Pharmacy Benefit Managers Fees Drive Up Drug CostsMarch 22nd 2017
A new trend in the way pharmacy benefit managers are collecting fees from pharmacy providers is driving up drug costs, gouging point-of-sale pharmacy operations, and playing havoc with spending at Centers for Medicare & Medicaid Services.
Anti-BCMA CAR T-Cell Therapy Approaches 80% Response Rate in Multiple MyelomaMarch 22nd 2017
An investigational anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy demonstrated an objective response rate of 78% in patients with relapsed/refractory multiple myeloma.
Mutational Load is Only One Piece of the Immunotherapy PuzzleMarch 22nd 2017
As immunotherapies become a greater part of the treatment paradigm of various cancers, researchers are spending more time developing ways to determine which patients will respond better to immunotherapy. Mutational load is one such biomarker that appears to have an impact on response to immunotherapy, particularly for checkpoint inhibitors.
Globetrotting Head and Neck Cancer Show Hits 8 CountriesMarch 22nd 2017
The International Federation of Head and Neck Oncologic Societies recently completed its fourth tour, with 8 experts in the field of head and neck oncology traveling to 8 countries over a month to offer continuing medical education courses on treatment paradigms and surgical techniques in head and neck cancer across the world.
Immunotherapy Making Its Mark on Head and Neck CancerMarch 22nd 2017
Following the approval of 2 immunotherapy agents, pembrolizumab and nivolumab for the treatment of patients with head and neck cancer over the last 6 months, immunotherapy is making its mark on the treatment paradigm for HNC.
Rare Cardiotoxicity Effects Founds With Checkpoint Inhibitors in MelanomaMarch 16th 2017
As the oncology community adapts to using immunotherapy agents more frequently in cancer treatments, the fear over immune-related adverse events (irAEs) prevents many clinicians from fully trusting immunotherapies.
Searching for the Key to Trastuzumab Cardiotoxicity in HER2+ Breast CancerMarch 10th 2017
Treatment with trastuzumab (Herceptin) has shown such a benefit in the treatment of patients with HER2-positive breast cancer that it is now the standard of care despite its association with cardiotoxicity. As such, researchers have taken to searching for ways to lessen or prevent the incidence of cardiac events in trials with trastuzumab.